Drug intelligence / Profile preview

Maxing Zhixiao Granule

Development stage: Unknown
Lead developer: Lianyungang Kanion
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Maxing Zhixiao Granule is a Traditional Chinese Medicine (TCM) formulation developed by Jiangsu Kanion Pharmaceutical for the treatment of chronic persistent bronchial asthma, specifically targeting the 'heat wheeze' (heat asthma) pattern. The drug is designed to clear heat, ventilate the lungs, and relieve cough and wheezing. It has been evaluated in multiple clinical trials in China, including Phase II and Phase III studies, to assess its efficacy and safety as a treatment for asthma symptoms.

Brand names: Maxing Zhixiao Granule
Other names: Ma Xing Zhi Xiao granulesMa Xing Zhi Xiao Keli

Targets

SMPD1 (Acid sphingomyelinase)

Beyond the preview

Go deeper on Maxing Zhixiao Granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Maxing Zhixiao Granule.

Explore the full profile